ArticleTranslational gastroenterology and hepatology2026
Landscape of clinical trials and impact of precision medicine in biliary tract cancers in the last 45 years: a systematic review and meta-analysis of biomarker-driven trials.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biliary tract cancers (BTCs) collectively are challenging tumors despite some advances in research in the last years. Although multiple efforts, challenges in clinical trial recruitment and positive outcomes persist. With the aim of understanding this landscape of clinical trials, a thorough analysis of clinical trials over the past 45 years was developed. Methods: A systematic search of Embase, PubMed, Scopus, and Web of Science was carried out, to identify prospective trials evaluating any intervention in patients with BTCs. Trials were included if they reported specific patient data for BTC. Data regarding epidemiological aspects and outcomes of all trials were extracted. A meta-analysis of randomized trials was performed to compare the efficacy of precision medicine over cytotoxic chemotherapy. Results: Among 427 trials involving 23,024 patients, 10.8% were phase I, 66% phase II, and 23.1% randomized or multicohort studies. Cholangiocarcinoma (CCA) was the focus in 85 trials (19.9%) while 22 trials (5.15%) didn't clearly report the BTC subtype. Median age was 63 years [interquartile range (IQR): 60-65 years], consistent across the study period. Race was explicitly reported in only 82 trials (19.2%), with 80% of patients identified as White and less than 5% as Black. From 2021 onwards, Asia has become the leading recruitment region. The amount of biomarker-based trials and immunotherapy trials more than doubled between the period 2020-2023. Among randomized first-line trials for advanced disease, sample sizes have increased over time, but median overall survival (OS) has remained approximately 12 months, despite the addition of cytotoxic agents or immunotherapy. In refractory settings, biomarker-driven trials doubled response rates compared to standard approaches [odds ratio (OR) =2.16]. Conclusions: Over the past 45 years, BTC trials have resulted in modest incremental survival. However, immunotherapy and precision medicine may change this paradigm, justifying the expansion of biomarker-driven approaches in earlier treatment settings. Limitations in patient diversity, reporting standards, and regional representation persist. Future efforts should focus on improving inclusivity and methodological consistency in BTC trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.